https://www.selleckchem.com/pe....ptide/gp91ds-tat.htm
We compared risk of acute liver injury and mortality in patients with COVID-19 and current, past, and no HBV infection. This was a territory-wide retrospective cohort study in Hong Kong. Patients with COVID-19 between January 23, 2020, and January 1, 2021, were identified. Patients with hepatitis C or no HBsAg results were excluded. The primary outcome was mortality. Acute liver injury was defined as alanine aminotransferase or aspartate aminotransferase ≥2 × upper limit of normal (ULN; i.e., 80U/L), with total bilirubin ≥2 × ULN (i.e
Like
Comment
Share
